Goserelin

Background

Goserelin is a synthetic decapeptide analogue of gonadotropin‑releasing hormone (GnRH; also LHRH), developed to provide sustained suppression of pituitary gonadotropin secretion and downstream sex steroid production.[11][15] It differs from native GnRH by amino acid substitutions (notably at positions 6 and 10) that enhance receptor affinity and resistance to enzymatic degradation, enabling depot formulations for long‑acting administration.[11]

Goserelin acetate was first developed in the late 1970s–1980s and commercialized as Zoladex, a subcutaneous biodegradable implant for 1‑ or 3‑month dosing.[15] Early clinical work focused on hormone‑sensitive cancers, particularly premenopausal advanced breast cancer and advanced prostate cancer, as a pharmacologic alternative to surgical oophorectomy or orchiectomy.[11][15] Subsequent development extended to endometriosis, uterine fibroids, and ovarian suppression in adjuvant breast cancer therapy.[11]

Mechanism of action

Receptor targets

Goserelin is a potent agonist at the pituitary GnRH receptor (GnRHR), a class A G‑protein‑coupled receptor expressed primarily on gonadotroph cells in the anterior pituitary.[11][15] It does not directly bind estrogen, progesterone, or androgen receptors; its endocrine effects are mediated through upstream modulation of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) secretion.[11]

Pharmacodynamic profile

When administered in a continuous depot form, goserelin produces a biphasic hormonal response:

• Initial flare: During the first 1–2 weeks, sustained receptor stimulation increases LH and FSH release, acutely raising circulating testosterone in men and estradiol in premenopausal women.[11][15]
• Subsequent down‑regulation: Continuous exposure leads to receptor desensitization and internalization, with marked suppression of LH/FSH, thereby reducing gonadal steroidogenesis to castrate or postmenopausal levels.[11][15]

In premenopausal women with advanced breast cancer, goserelin produces serum estradiol concentrations comparable to surgical oophorectomy or natural menopause.[15] In men with prostate cancer, testosterone typically falls to castrate levels (≤50 ng/dL) within 2–4 weeks and is maintained with repeated dosing.[14]

Other pharmacologic considerations

Preclinical studies of extended‑release microspheres containing goserelin (LY01005) demonstrate a sustained‑release profile with continuous in vivo suppression of testosterone and comparable pharmacodynamic potency to Zoladex implants, confirming that effects are driven by systemic exposure to goserelin itself.[14]

Evidence summary

Breast cancer

Early work in premenopausal advanced breast cancer established goserelin as an effective endocrine therapy. A German multicenter trial (“German Zoladex Trial Group”) evaluated depot goserelin in premenopausal women with metastatic breast cancer, demonstrating objective responses and estradiol suppression to postmenopausal levels.[11] A later series of 75 premenopausal patients with advanced breast cancer treated with goserelin (Zoladex) reported response rates and duration of response consistent with those seen after surgical oophorectomy, supporting its role as medical ovarian ablation.[15]

Goserelin has also been extensively evaluated in early breast cancer. An overview of ongoing large international trials described four major studies:

• The ZEBRA trial (Zoladex Early Breast Cancer Research Association; goserelin vs cyclophosphamide–methotrexate–5‑fluorouracil [CMF]).
• A Cancer Research Campaign (CRC) trial (goserelin vs tamoxifen vs combination vs no further treatment).
• International Breast Cancer Study Group trial VIII and other cooperative group studies, examining goserelin‑based ovarian suppression in adjuvant settings.[11]

These trials test goserelin as an alternative or addition to chemotherapy and tamoxifen in hormone receptor–positive premenopausal early breast cancer, with endpoints including disease‑free survival and overall survival.[11] Later analyses outside the cited review have generally supported the benefit of ovarian suppression plus endocrine therapy in appropriately selected high‑risk premenopausal patients.

Prostate cancer

Although detailed randomized data are not provided in the retrieved articles, goserelin is a well‑established standard of care in advanced and locally advanced prostate cancer. Its efficacy derives from reliable achievement and maintenance of castrate testosterone levels, with clinical outcomes comparable to surgical orchiectomy.[14] Preclinical evaluation of LY01005 in rats demonstrated sustained suppression of testosterone and LH, reduction in androgen‑dependent accessory organ weights, and a safety profile broadly similar to Zoladex, reinforcing the class mechanism.[14]

Other indications and experimental work

Goserelin is widely used for benign gynecologic conditions such as endometriosis and uterine fibroids based on its ability to induce a reversible hypoestrogenic state; detailed clinical trials are not captured in the provided search set but are well documented in regulatory labels.

In silico drug‑repurposing work has explored goserelin (Zoladex) as a potential acetylcholinesterase inhibitor for Alzheimer’s disease. A molecular docking and dynamics study identified Zoladex and another peptide (CHEMBL‑1240685) as having favorable binding energies and stability compared with donepezil and galantamine.[12][13] However, literature indicating that goserelin can impair memory led authors to reject it as a repurposing candidate, and there is no clinical evidence for its use in neurodegenerative disease.[12][13]

Clinical and research uses

Approved therapeutic uses (US/EU context)

Based on regulatory and clinical literature (not all captured in the limited search set but established in standard references), goserelin is approved as a GnRH agonist depot for:

• Prostate cancer: palliative treatment of advanced prostate cancer; part of combined androgen deprivation therapy in locally advanced or high‑risk disease.
• Breast cancer: treatment of hormone receptor–positive breast cancer in premenopausal women, particularly advanced/metastatic disease and as ovarian suppression in adjuvant endocrine therapy.[11][15]
• Endometriosis: induction of hypoestrogenism to reduce endometriosis‑related pain and lesion activity.
• Uterine fibroids: preoperative reduction in fibroid and uterine volume and improvement in anemia.
• Ovarian suppression: for controlled ovarian hyperstimulation protocols and fertility preservation strategies in some settings.

Investigational and off‑label uses

• Fertility preservation: Use of goserelin during chemotherapy to reduce the risk of chemotherapy‑induced ovarian failure is supported by randomized data outside the provided set; this is guideline‑endorsed but may be considered adjunctive rather than primary fertility preservation.
• Neuroendocrine and other hormone‑dependent tumors: Occasional off‑label use has been reported for rare GnRH‑responsive tumors.
• Drug delivery innovations: LY01005 and other extended‑release microsphere formulations are in development to provide alternative dosing intervals or improved injection characteristics, with preclinical rat data indicating similar efficacy and safety to existing implants.[14]

Dosing context

The following regimens summarize common schedules reported in clinical and regulatory literature; they are not prescribing recommendations:

• Prostate cancer:
  • Goserelin acetate depot implants commonly formulated as 3.6 mg (approximately 1‑month depot) or 10.8 mg (approximately 3‑month depot), administered subcutaneously into the abdominal wall and repeated at fixed intervals to maintain castrate testosterone.
• Premenopausal breast cancer / ovarian suppression:
  • Similar depot strengths (e.g., 3.6 mg every 28 days) are used to maintain estradiol in the postmenopausal range.[11][15]
• Endometriosis and fibroids:
  • Typically given as monthly or 3‑monthly depot injections for limited durations (commonly 3–6 months) due to hypoestrogenic adverse effects.

In preclinical studies, LY01005 microspheres were administered to rats with dosing designed to approximate human exposure from standard Zoladex regimens, demonstrating sustained goserelin plasma concentrations and hormonal suppression over the intended dosing interval.[14]

Safety profile

Class and drug‑specific adverse effects

Adverse effects largely reflect hypogonadism and the initial hormone flare:

• Endocrine and metabolic: hot flushes, sweating, decreased libido, erectile dysfunction, vaginal dryness, amenorrhea, weight changes, and reduced bone mineral density with prolonged use.
• Musculoskeletal: arthralgia, myalgia, accelerated bone loss and increased fracture risk with long‑term therapy.
• Neuropsychiatric: mood changes, depression, and memory or cognitive complaints are reported clinically and supported indirectly by the Alzheimer’s in silico study, which references literature on goserelin‑associated memory reduction.[12][13]
• Cardiovascular and metabolic risk: long‑term androgen deprivation is linked to unfavorable lipid changes, insulin resistance, and possible increased cardiovascular risk, as with other GnRH agonists.
• Tumor flare phenomena: In prostate cancer, the initial testosterone surge may transiently exacerbate symptoms (bone pain, urinary obstruction, spinal cord compression risk). In breast cancer, an initial estradiol rise could theoretically worsen symptoms; co‑administration of antiandrogens (for prostate) or other agents around initiation is a standard mitigation strategy.

Preclinical safety data

In rats, extended‑release goserelin microspheres (LY01005) produced expected pharmacologic effects on androgen‑dependent organs (reduced weights of testes, epididymis, and prostate) consistent with GnRH agonism.[14] Mild histopathological changes related to foreign body reaction at the injection site were observed, attributed to excipients rather than goserelin itself.[14] Overall toxicologic findings were similar to those of Zoladex, supporting a comparable safety profile.[14]

Bone health and hypoestrogenism

Although not detailed in the retrieved articles, extensive clinical experience indicates that prolonged goserelin therapy in both sexes can lead to progressive bone mineral density loss. In benign gynecologic indications, treatment courses are often time‑limited and sometimes combined with “add‑back” low‑dose sex steroids to mitigate hypoestrogenic symptoms and bone loss.

Contraindications and precautions

Contraindications and cautions, as reflected in regulatory labeling and clinical practice, generally include:

• Known hypersensitivity to goserelin, other GnRH agonists, or any implant components.
• Pregnancy: goserelin is contraindicated in pregnancy due to potential fetal harm; nonhormonal contraception is recommended during and for a period after treatment in women of childbearing potential.
• Breastfeeding: generally not recommended during therapy.
• High risk of spinal cord compression or ureteric obstruction: requires close monitoring and sometimes prophylactic measures during the initial flare in prostate cancer.
• Pre‑existing severe osteoporosis or major risk factors for bone loss: necessitates careful risk–benefit assessment and bone‑protective strategies.

Regulatory status

Goserelin acetate (Zoladex and generic equivalents) is an established, widely approved GnRH agonist depot in both the United States and European Union.

• In the US, goserelin is approved by the Food and Drug Administration as a subcutaneous implant for:

  • Palliative treatment of advanced prostate cancer.
  • Use in the management of endometriosis.
  • Use as an adjunct in endometrial thinning prior to endometrial ablation.
  • Treatment of premenopausal women with hormone receptor–positive breast cancer, usually as part of endocrine therapy regimens.

• In the EU, the European Medicines Agency and national regulators have authorized goserelin for broadly similar indications, including prostate cancer, premenopausal breast cancer, endometriosis, uterine fibroids (preoperative use), and assisted reproduction protocols.

Extended‑release microsphere formulations such as LY01005 are currently at the developmental stage, with preclinical toxicology and pharmacology published and planned clinical trials indicated, but they are not yet standard approved products.[14]